Tumor specific liposomes improve detection of XXXX in vivo using optoacoustic tomography.

@entity788 @entity2667 @entity19 @entity5 @entity7423 @entity10828
BACKGROUND: @entity788 often goes undiagnosed until late stage disease due in part to suboptimal early detection. Our goal was to develop a @entity10828 tagged liposome containing fluorescent dye as an improved contrast agent for detection of @entity788 in vivo using multispectral optoacoustic tomography. RESULTS: The diagnostic capabilities and specificity to @entity788 of @entity10828 targeted liposomes were evaluated both in vitro and in vivo. Immunocytochemistry showed that liposomes preferentially bound to and released their contents into cells expressing high levels of insulin-like growth factor 1 receptor. We determined that the contents of the liposome were released into the cell as noted by the change in @entity2667 fluorescence from green to red based upon nucleic acid binding. In an orthotopic @entity19 model, the liposomes preferentially targeted the @entity788 with little off-target binding in the liver and spleen. Peak accumulation of the liposomes in the @entity5 occurred at 8  h post-injection. Multispectral optoacoustic tomographic imaging was able to provide high-resolution 3D images of the @entity5 and liposome location. Ex vivo analysis showed that non-targeted liposomes accumulated in the liver, suggesting that specificity of the liposomes for @entity788 was due to the presence of the @entity10828 ligand. CONCLUSIONS: This study demonstrated that @entity10828 liposomes were able to release cargo into @entity7423 expressing @entity5 cells. The @entity10828 liposomes demonstrated @entity5 specificity in orthotopic pancreatic @entity5 as observed using multispectral optoacoustic tomography with reduced kidney and liver uptake. By targeting the liposome with @entity10828 , this nanovehicle has potential as a targeted theranostic nanoparticle for both drug and contrast agent delivery to @entity788 .
